Back to Search
Start Over
Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L)
- Source :
- JTO Clinical and Research Reports; October 2023, Vol. 4 Issue: 10
- Publication Year :
- 2023
-
Abstract
- Docetaxel plus ramucirumab could be a promising treatment for chemo-naive elderly patients with NSCLC, but high incidence of febrile neutropenia (FN) is a critical concern. We thus adopted a routine primary prophylactic pegylated-granulocyte-colony stimulating factor (PEG-G-CSF) to reduce FN and maximize the efficacy of docetaxel plus ramucirumab in elderly patients.
Details
- Language :
- English
- ISSN :
- 26663643
- Volume :
- 4
- Issue :
- 10
- Database :
- Supplemental Index
- Journal :
- JTO Clinical and Research Reports
- Publication Type :
- Periodical
- Accession number :
- ejs63916619
- Full Text :
- https://doi.org/10.1016/j.jtocrr.2023.100569